Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib

Conclusion: Performing 18F-FDG PET for early evaluation of response often results in a change of management in GIST patients harboring the non–KIT exon 11 mutation and should be considered the standard of care in GIST patients treated with neoadjuvant intent.

Source: Journal of Nuclear Medicine - February 1, 2018 Category: Nuclear Medicine Authors: Farag, S., Geus-Oei, L.-F. d., van der Graaf, W. T., van Coevorden, F., Grunhagen, D., Reyners, A. K. L., Boonstra, P. A., Desar, I., Gelderblom, H., Steeghs, N. Tags: Clinical Source Type: research